Medicago and GlaxoSmithKline (GSK) have started Phase III clinical testing of Medicago’s plant-derived COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, as part of the ongoing Phase II/III study. Medicago received approval from Canadian and US regulatory authorities to proceed with enrolment of healthy adults in the Phase III portion of the trial based on positive interim Phase II results.
Medicago’s plant-derived vaccine candidate against COVID-19 uses Coronavirus-Like-Particle (CoVLP) technology with the vaccine composed of recombinant spike (S) glycoprotein expressed as virus-like-particles (VLPs) co-administered with GSK’s pandemic adjuvant. Two doses of 3.75μg of CoVLP are administered 21 days apart.
The vaccine candidate, in combination with the pandemic adjuvant, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) on 17 February 2021. Fast Track designation allows the FDA to expedite the development and review of new medicines and vaccines intended to treat or prevent serious conditions and address an unmet medical need.
The Phase II portion of the trial is approaching completion and results are expected to be made publicly available in April 2021.
Takashi Nagao, CEO and President of Medicago said: “We are pleased to take the significant step of initiating the Phase III clinical trial at sites around the world. This brings us one step closer to delivering an important new COVID-19 vaccine and contributing to the global fight against the pandemic along with our partner GSK.”
Thomas Breuer, Chief Medical Officer, GSK Vaccines said, “This advance to late-stage clinical testing further reinforces our confidence in the adjuvanted vaccine candidate’s potential to make a difference in the continued fight against COVID-19. We look forward to sharing results later this year.”
Carolyn Finkle, Chief Operating Officer of Medicago said: “The FDA’s decision to grant Fast Track designation for Medicago’s vaccine candidate will help us expedite our efforts to bring the first plant-derived COVID-19 vaccine to market, subject to regulatory approval. We are grateful to the FDA and look forward to continuing to work with them as we move forward in our clinical trials, planned application for Emergency Use Authorisation and eventual vaccine licensure application process.”